Advertisement

International Journal of Hematology

, Volume 75, Issue 1, pp 40–44 | Cite as

Detection of CD55- and/or CD59-Deficient Red Cell Populations in Patients With Plasma Cell Dyscrasias

  • John Meletis
  • Evangelos Terpos
  • Michalis Samarkos
  • Christos Meletis
  • Effie Apostolidou
  • Veroniki Komninaka
  • Konstantinos Korovesis
  • Konstantinos Anargyrou
  • Olga Benopoulou
  • Despina Mavrogianni
  • Eleni Variami
  • Nora Viniou
  • Konstantinos Konstantopoulos
Progress in Hematology

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal disorder characterized by a decrease or absence of gly-cosylphosphatidylinositol (GPI)-anchored molecules such as CD55 and CD59 from the surface of affected cells, resulting in intravascular hemolysis, cytopenia, and venous thrombosis. A PNH-like phenotype has been detected in various hematologi-cal disorders, mainly in aplastic anemia and myelodysplastic syndromes, but also in lymphoproliferative syndromes (LPSs).To the best of our knowledge, CD55- or CD59-deficient red cells have not been detected in plasma cell dyscrasias (PCDs). The aim of this study was the detection of CD55- and/or CD59-deficient red cell populations in patients with PCD. Seventy-seven patients were evaluated; 62 with multiple myeloma (MM), 7 with Waldenström macroglobulinemia (WM), 6 with monoclonal gammopathy of undetermined significance (MGUS), and 2 with heavy chain disease (HCD). The sephacryl gel microtyping system was applied; Ham and sucrose lysis tests were also performed on all samples with CD55- or CD59-negative populations. Red cells deficient in both molecules were detected in 10 (12.9%) of 77 patients with PCD: 2 (28.6%) of 7 with WM, 1 (16.6%) of 6 with MGUS, 6 (9.6%) of 62 with MM, and 1 of 2 patients with HCD. Isolated CD55 deficiency was found in 28.5% of all PCD patients, whereas isolated CD59 deficiency was not observed in any patients.These findings illustrate the existence of the PNH phenotype in the red cells of patients with PCD; further investigation is needed into the mechanisms and significance of this phenotype.

Key words

Paroxysmal nocturnal hemoglobinuria CD55 CD59 Multiple myeloma Waldenström macroglobulinemia 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rotoli B, Luzzatto L. Paroxysmal nocturnal hemoglobinuria.Semin Hematol. 1989;26:201–207.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Luzzatto L, Bessler M. The dual pathogenesis of paroxysmal nocturnal hemoglobinuria.Curr Opin Hematol. 1996;3:101–110.CrossRefPubMedGoogle Scholar
  3. 3.
    Rosti V. The molecular basis of paroxysmal nocturnal hemoglobin- uria.Haematologica. 2000;85:82–87.PubMedGoogle Scholar
  4. 4.
    Rosse WF, Ware R. The molecular basis of paroxysmal nocturnal hemoglobinuria.Blood. 1995;86:3277–3286.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Murakami Y, Kinoshita T, Maeda Y, Nakano T, Kosaka H, Takeda J. Different roles of glycosylphosphatidylinositol in various hematopoietic cells as revealed by a mouse model of paroxysmal nocturnal hemoglobinuria.Blood. 1999;94:2963–2970.PubMedGoogle Scholar
  6. 6.
    Griscelli-Bennaceur A, Gluckman E, Scrobohaci ML, et al. Aplastic anemia and paroxysmal nocturnal hemoglobinuria: search for a pathogenetic link.Blood. 1995;85:1354–1363.PubMedGoogle Scholar
  7. 7.
    Dunn DE, Tanawattanacharoen P, Boccuni P, et al. Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes.Ann Intern Med. 1999;131:401–408.CrossRefPubMedGoogle Scholar
  8. 8.
    Meletis J, Terpos E, Samarkos M, et al. Detection of CD55 and/or CD59 deficient red cell populations in patients with aplastic anaemia, myelodysplastic syndromes and myeloproliferative disorders.Haematologica (Budap). 2001;31:7–16.CrossRefGoogle Scholar
  9. 9.
    Guc D, Canpinar H, Kucukaksu C, Kansu E. Expression of complement regulatory proteins CR1, DAF, MCP and CD59 in haema- tological malignancies.Eur J Haematol. 2000;64:3–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Hertenstein B, Wagner B, Bunjes D, et al. Emergence of CD52-, phosphatidylinositolglycan-anchor-deficient T lymphocytes after in vivo application of Campath-1H for refractory B-cell non-Hodgkin lymphoma.Blood. 1995;86:1487–1492.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Meletis J, Terpos E, Samarkos M, et al. Detection of CD55 and/or CD59 deficient red cell populations in patients with lymphoprolif- erative syndromes.Hematol J. 2001;2:33–37.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Meletis J, Terpos E. Paroxysmal nocturnal haemoglobinuria: clinical presentation and association with other haematological disorders.Haema. 2001;4:79–88.Google Scholar
  13. 13.
    Nilsson BO, Hagstrom U, Englund A, Safwenberg J. A simplified assay for the specific diagnosis of paroxysmal nocturnal hemoglo- binuria: detection of DAF (CD55)- and HRF20 (CD59)- erythro- cytes in microtyping cards.Vox Sang. 1993;64:43–46.PubMedGoogle Scholar
  14. 14.
    Meletis J, Michali E, Samarkos M, et al. Detection of “PNH red cell” populations in hematological disorders using the Sephacryl Gel Test micro typing system.Leuk Lymphoma. 1997;28:177–182.CrossRefPubMedGoogle Scholar
  15. 15.
    Fukuda H, Seya T, Hara T, Matsumoto M, Kinoshita T, Masaoka T. Deficiency of complement decay-accelerating factor (DAF, CD55) in non-Hodgkin’s lymphoma.Immunol Lett. 1991;29:205–209.CrossRefPubMedGoogle Scholar
  16. 16.
    Seya T, Matsumoto M, Hara T, Hatanaka M, Masaoka T, Akedo H. Distribution of C3-step regulatory proteins of the complement system, CD35 (CR1), CD46 (CMP) and CD55 (DAF) in hematologi- cal malignancies.Leuk Lymphoma. 1994;12:395–400.CrossRefPubMedGoogle Scholar
  17. 17.
    Sun X, Funk CD, Deng C, Sahu A, Lambris JD, Song WC. Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting.Proc Natl Acad Sci U S A. 1999;96:628–633.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Hillmen P, Richards SJ. Implications of recent insights into the pathophysiology of paroxysmal nocturnal haemoglobinuria.Br J Haematol. 2000;108:470–479.CrossRefPubMedGoogle Scholar
  19. 19.
    Taylor VC, Sims M, Brett S, Field MC. Antibody selection against CD52 produces a paroxysmal nocturnal hemoglobinuria pheno- type in human lymphocytes by a novel mechanism.Biochem J. 1997;322:919–925.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Rawstron AC, Rollinson SJ, Richards S, et al. The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatment.Br J Haematol. 1999;107:148–153.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Araten D, Nafa K, Pakdeesuwan K, Luzzatto L. Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals.Proc Natl Acad Sci U S A. 1999;96:5209–5214.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Kwong YL, Lee CP, Chan TK, Chan TC. Flow cytometric measurement of glycosylphosphatidyl-inositol-linked surface proteins on blood cells of patients with paroxysmal nocturnal hemoglobinuria.Am J Clin Pathol. 1994;102:30–35.CrossRefPubMedGoogle Scholar
  23. 23.
    Tremml G, Karadimitris A, Luzzatto L. Paroxysmal nocturnal hemoglobinuria: learning about PNH cells from patients and mice.Haema. 1998;1:12–20.Google Scholar

Copyright information

© The Japanese Society of Hematology 2002

Authors and Affiliations

  • John Meletis
    • 1
  • Evangelos Terpos
    • 1
  • Michalis Samarkos
    • 1
  • Christos Meletis
    • 2
  • Effie Apostolidou
    • 1
  • Veroniki Komninaka
    • 1
  • Konstantinos Korovesis
    • 1
  • Konstantinos Anargyrou
    • 1
  • Olga Benopoulou
    • 1
  • Despina Mavrogianni
    • 1
  • Eleni Variami
    • 1
  • Nora Viniou
    • 1
  • Konstantinos Konstantopoulos
    • 1
  1. 1.First Department of Internal Medicine, University of Athens School of MedicineLaiko General HospitalAthens
  2. 2.Department of Electrical and Computer EngineeringNational Technical University of AthensAthensGreece

Personalised recommendations